Raymond James reiterates Outperform on Regeneron stock at $910 target

Raymond James reiterated an Outperform rating on Regeneron and a $910 price target, while Bernstein lifted its target to $921, signaling continued analyst support. The update highlighted Regeneron's C5 program, with key catalysts expected in Q4 2026, including a PDUFA decision in generalized myasthenia gravis, pivotal PNH data, and initial Phase 3 geographic atrophy results. The piece also noted Regeneron’s $743 share price, 28% six-month return, and $14.3 billion in annual revenue, but the news is primarily analyst commentary rather than a major fresh corporate development.

Analysis

REGN looks like a classic case where the market is still underpricing platform optionality relative to the nearer-term commercial base. The key second-order effect is that a credible complement-inhibitor franchise can re-rate the whole immunology pipeline, not just the lead indication: once physicians see differentiation on durability and dosing convenience, follow-on labels become easier to penetrate and payer friction falls faster than usual. The setup is especially attractive because the market is assigning value to a single asset story while the next 12-18 months contain multiple binary readouts that can independently lift the multiple.

The bigger competitive implication is not just displacement of other C5 inhibitors, but pressure on adjacent rare-disease and ophthalmology platforms that rely on chronic administration and premium pricing. If the combination proves cleaner in both efficacy and logistics, the market may start discounting incumbents’ growth durability before the revenue numbers fully turn. That would also create a spillover benefit for TLX if investors start to view the collaboration as evidence that REGN is increasingly willing to use capital-light partnerships to broaden the pipeline without diluting margin structure.

The contrarian risk is timing: this can work fundamentally while underperforming tactically if the market de-risks the 2026 catalysts too slowly and treats the current move as already “paid for.” Another hidden risk is that early enthusiasm on the combination could overstate peak share capture if prescribers anchor to established standards in the first 6-9 months post-launch. For the next several quarters, the trade is less about absolute upside versus disappointment and more about whether each incremental data point reduces the probability-weighted gap between current valuation and the long-duration earnings stream.

Key Decisions for Investors

• Go long REGN on pullbacks toward the low-700s with a 6-12 month horizon; target a re-rating into catalyst season, with downside capped if the market starts capitalizing the 2026 pipeline optionality.
• Buy REGN Jan-2027 call spreads to express the catalyst ladder while limiting theta burn; structure around the 2026 PDUFA/data cluster and use a spread to avoid overpaying for implied volatility.
• Pair long REGN / short a basket of mature biologics with slower growth and similar valuation multiples; the relative trade favors names with more binary pipeline leverage over pure cash-flow compounds.
• Use TLX as a smaller satellite long only if you want exposure to the strategic collaboration angle; size modestly because the read-through is narrative-driven, not yet earnings-driving.
• If REGN rallies sharply ahead of the 4Q26 data window, trim 25-30% into strength and keep the rest for binary upside; the market will likely front-run the catalysts well before fundamentals inflect.